Known targets — ChEMBL curated mechanism
ACHEADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3APH1AAPH1BCHRM2CHRM3EZH2GRIN2AHTR1AHTR1BHTR1DHTR1FHTR3ANCSTNP2RY12PSEN1PSEN2PSENENSIGMAR1SLC6A2SLC6A3SLC6A4
The experimentally established mechanism targets of Bromide. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK1 | P28482 | 2/20 | 0.61 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.51 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.51 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.51 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.47 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.44 |
| ▸ | HCRTR2 | O43614 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12012125 | 0.98 | MAPK1 (0.62) | MAPK1CYP1A2TDP1ALOX15ALOX12 | |
| SCHEMBL10512497 | 0.84 | MAPK1 (0.64) | MAPK1CYP1A2TDP1ALOX15ALOX12 | |
| SCHEMBL2338659 | 0.79 | MAPK1 (0.65) | MAPK1CYP1A2TDP1ALOX15ALOX12 | |
| SCHEMBL269695 | 0.79 | MAPK1 (0.65) | MAPK1CYP1A2TDP1ALOX15ALOX12 | |
| SCHEMBL951841 | 0.78 | MAPK1 (0.63) | MAPK1CYP1A2TDP1ALOX15ALOX12 | |
| SCHEMBL952278 | 0.76 | MAPK1 (1.00) | MAPK1CYP1A2ALOX15HCRTR1 | |
| SCHEMBL9516847 | 0.74 | MAPK1 (0.59) | MAPK1CYP1A2TDP1ALOX15ALOX12 | |
| SCHEMBL10514007 | 0.74 | MAPK1 (0.66) | MAPK1CYP1A2TDP1ALOX15 | |
| Bromide SCHEMBL2339034 | 0.72 | ALOX12 (0.50) | MAPK1CYP1A2TDP1ALOX15ALOX12 | |
| Bromide SCHEMBL21996101 | 0.72 | KMT2A (0.66) | MAPK1CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3173414-A1 | HETEROCYCLIC COMPOUNDS AND USES AS ANTICANCER AGENTS | ACEA Biosciences Inc. (US) | 2017-05-31 | — | — | EP | disclosed |
| EP-2536719-A1 | HETEROCYCLIC COMPOUNDS AND USES AS ANTICANCER AGENTS | Acea Biosciences, Inc. (US) | 2012-12-26 | — | — | EP | disclosed |
| US-8252822-B2 | Heterocyclic compounds and uses as anticancer agents | ACEA BIOSCIENCES, INC. (US) | 2012-08-28 | — | — | US | disclosed |
| US-20110207751-A1 | HETEROCYCLIC COMPOUNDS AND USES AS ANTICANCER AGENTS | ACEA Therapeutics, Inc. | 2011-08-25 | — | — | US | disclosed |
| WO-2011103509-A1 | HETEROCYCLIC COMPOUNDS AND USES AS ANTICANCER AGENTS | ACEA BIOSCIENCES INC. (US) | 2011-08-25 | — | — | WO | disclosed |
| US-20090048271-A1 | HETEROCYCLIC COMPOUNDS AND USES AS ANTICANCER AGENTS | ACEA Therapeutics, Inc. | 2009-02-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090048271-A1 | HETEROCYCLIC COMPOUNDS AND USES AS ANTICANCER AGENTS | MKI67, CCNC, HCCS | MAPK1 3031/4885CYP1A2 2379/4885TDP1 2861/4885 |
| US-20110207751-A1 | HETEROCYCLIC COMPOUNDS AND USES AS ANTICANCER AGENTS | MKI67, CCNC, NUDC | MAPK1 2649/4885CYP1A2 2630/4885TDP1 2040/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.